IL6 and Cognitive impairment: Clinical studies aim to assess whether modulation of the IL-6 axis can impact positive and negative symptoms as well as cognitive deficits in patients with SCZ, supporting the concept of immunomodulatory strategies in the treatment of this disorder [209].